



*Artemis Cardiac Care Private  
Limited*

**ANNUAL REPORT**

*2020-21*



## **NOTICE OF ANNUAL GENERAL MEETING**

**NOTICE** is hereby given that the Second Annual General Meeting of the members of **Artemis Cardiac Care Private Limited** ("the Company") will be held on Thursday, July 15, 2021 at 03:00 P.M. (IST) at Plot No. 14, Sector – 20, Dwarka, Delhi – 110075 to transact the following business:

1. To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2021 and the reports of the Board of Directors and of the Auditors thereon.
2. To appoint a Director in place of Dr. (Col) Manjinder Singh Sandhu (DIN: 08409644), who retires by rotation, and being eligible, offers himself for re-appointment.

**By Order of the Board of Directors  
For Artemis Cardiac Care Private Limited**

**Place: Gurugram  
Date: May 7, 2021**

**Sd/-  
(Shilpa Budhia)  
Company Secretary  
Membership No. A23564  
Address: Artemis Hospital,  
Sector-51, Gurugram-122001**

### **ARTEMIS CARDIAC CARE PRIVATE LIMITED**

Registered Office: Plot No. 14, Sector-20, Dwarka, New Delhi-110075

GST: 07AARCA7906R1ZR | CIN No: U85110DL2019PTC344351 | PAN: AARCA7906R | TAN: DELA52761C

Landline: 0124-4588855 | Email: shilpa.budhia@artemishospitals.com

**Notes:**

1. A Statement pursuant to Section 102(1) of the Companies Act, 2013 (“the Act”) relating to the Special Business to be transacted at the Annual General Meeting (“AGM”) is not required since there is no Special Business to be transacted in AGM.
2. **A MEMBER ENTITLED TO ATTEND AND VOTE AT THE AGM IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON A POLL INSTEAD OF HIMSELF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. THE INSTRUMENT APPOINTING PROXY SHOULD, HOWEVER, BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY NOT LESS THAN FORTY-EIGHT HOURS BEFORE THE COMMENCEMENT OF THE AGM.**

**A PERSON CAN ACT AS A PROXY ON BEHALF OF MEMBERS NOT EXCEEDING FIFTY AND HOLDING IN THE AGGREGATE NOT MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS. A MEMBER HOLDING MORE THAN TEN PERCENT OF THE TOTAL SHARE CAPITAL OF THE COMPANY CARRYING VOTING RIGHTS MAY APPOINT A SINGLE PERSON AS PROXY AND SUCH PERSON SHALL NOT ACT AS A PROXY FOR ANY OTHER PERSON OR SHAREHOLDER. THE PROXY HOLDER SHALL PROVE HIS IDENTITY AT THE TIME OF ATTENDING THE AGM. THE INSTRUMENT OF THE PROXY IN ORDER TO BE EFFECTIVE, SHOULD BE DEPOSITED AT THE REGISTERED OFFICE OF THE COMPANY, DULY COMPLETED AND SIGNED, NOT LESS THAN 48 HOURS BEFORE THE COMMENCEMENT OF THE AGM.**

3. During the period beginning 24 hours before the time fixed for the commencement of the AGM and ending with the conclusion of the AGM, a member would be entitled to inspect the proxies lodged at any time during the business hours of the Company, provided that not less than three days of notice in writing is given to the Company.
4. Attendance slip, proxy form and the route map of the venue of the AGM are annexed hereto.
5. Corporate members intending to send their authorised representative(s) to attend the AGM are requested to send to the Company a certified true copy of the relevant Board Resolution together with the specimen signature(s) of the representative(s) authorised under the said Board Resolution to attend and vote on their behalf at the AGM.
6. The Register of Directors & KMPs and their shareholding maintained under Section 170 of the Act and the Register of Contracts or Arrangement in which Directors are interested maintained under Section 189 of the Act, will be available for inspection by the members at the AGM.
7. Relevant documents referred to in the Notice are open for inspection by the members at the Registered Office of the Company on all working days (i.e. except Saturdays, Sundays and Public Holidays) during business hours up to the date of the AGM. The aforesaid documents will be also available for inspection by members at the AGM.
8. Members may also note that the Notice of the 2<sup>nd</sup> AGM is also available on the Company’s website <https://www.artemiscardiac.com/> for their download.
9. Members / Proxies / Authorised Representatives are requested to bring to the AGM necessary details of their shareholding, attendance slip(s) and copies of Annual Report.
10. Pursuant to Section 118 (10) and other applicable provisions of the Act read with Revised Secretarial Standards for General Meetings (SS-2), the details of Director seeking appointment are given as a separate Annexure 1 to this Notice.

**Annexure 1**

**DETAILS OF DIRECTOR SEEKING APPOINTMENT AS REQUIRED UNDER THE SECRETARIAL  
STANDARD-2 ON GENERAL MEETINGS**

<b>Name of the Director</b>	Dr. (Col) Manjinder Singh Sandhu
<b>Date of Birth</b>	07/03/1964
<b>Date of Appointment on the Board</b>	03/04/2019
<b>Qualification(s)</b>	MBBS, MD, FACC
<b>Expertise</b>	He had a distinguished career in the Army Medical Corps and was last posted as Senior Adviser (Medicine and Cardiology) at Base Hospital, Delhi Cantt and was also holding appointment of Addl. Professor of Medicine and Cardiology at Army College of Medical Sciences, Delhi Cant.
<b>Directorships held in other public companies including private companies which are subsidiaries of public companies (excluding foreign companies)</b>	NIL
<b>Memberships/ Chairmanships of committees across all companies</b>	NIL
<b>Number of Meetings attended during the year</b>	4 out of 4
<b>Shareholding</b>	NIL
<b>Key terms and conditions of appointment</b>	Non-Executive Director, liable to retire by rotation.
<b>Remuneration sought to be paid</b>	NIL
<b>Remuneration last drawn</b>	NIL
<b>Numbers of Shares held in the Company</b>	NIL
<b>Relationships between directors inter-se</b>	N.A

## Form No. MGT-11

### Proxy form

[Pursuant to section 105(6) of the Companies Act, 2013 and rule 19(3) of the Companies (Management and Administration) Rules, 2014]

**CIN** : U85110DL2019PTC344351  
**Name of the Company** : Artemis Cardiac Care Private Limited  
**Registered Office** : Plot No. 14, Sector-20, Dwarka, Delhi-110 075

Name of the Member(s):	
Registered Address:	
E-mail ID:	
Folio No/ Client Id:	
DP ID:	

I/We, being the member (s) of ..... shares of the above named company, hereby appoint:

1. Name:

Address:

E-mail Id:

Signature: ..... or failing him

2. Name:

Address:

E-mail Id:

Signature: ..... or failing him

and whose signature(s) are appended below as my/our proxy to attend and vote (on a poll) for me/us and on my/our behalf at the Second Annual General Meeting of the members of the Company, to be held on Thursday, July 15, 2021 at 03:00 P.M. (IST) at the Registered Office of the Company and at any adjournment thereof in respect of such resolutions as are indicated below:

	Resolution No.	Optional	
		For	Against
1.	To receive, consider and adopt the audited financial statements of the Company for the financial year ended March 31, 2021 and the reports of the Board of Directors and of the Auditors thereon.		
2.	To appoint a Director in place of Dr. (Col) Manjinder Singh Sandhu (DIN: 08409644), who retires by rotation, and being eligible, offers himself for re-appointment.		

Signed this..... day of..... 2021

Signature of shareholder .....

Signature of Proxy holder(s).....

AFFIX  
REVENUE  
STAMP

**Note:**

1. This form of proxy in order to be effective should be duly completed and deposited at the Registered Office of the Company, not less than 48 hours before the commencement of the Meeting.
2. A proxy need not be a member of the Company and shall prove his identity at the time of attending the Meeting.
3. A person can act as a proxy on behalf of members not exceeding fifty and holding in the aggregate not more than 10% of the total share capital of the Company carrying voting rights. A Member holding more than 10% of the total share capital of the Company carrying voting rights may appoint a single person as proxy and such person shall not act as a proxy for any other person or shareholder.
4. This is only optional. Please put a 'V' in the appropriate column against the resolutions indicated in the Box. If you leave the 'For' or 'Against' column blank against any or all the resolutions, your Proxy will be entitled to vote (on poll) at the Meeting in the manner as he/she thinks appropriate.
5. Appointing a proxy does not prevent a member from attending the Meeting in person if he/ she so wishes. When a Member appoints a Proxy and both the Member and Proxy attend the Meeting, the Proxy will stand automatically revoked.
6. In the case of joint holders, the signature of any one holder will be sufficient, but names of all the joint holders should be stated.
7. This form of proxy shall be signed by the appointer or his attorney duly authorized in writing, or if the appointer is a body corporate, be under its seal or be signed by an officer or an attorney duly authorized by it.
8. This form of proxy will be valid only if it is duly complete in all respects, properly stamped and submitted as per the applicable law. Incomplete form or form which remains unstamped or inadequately stamped or form upon which the stamps have not been cancelled will be treated as invalid.
9. If Company receives multiple proxies for the same holdings of a member, the proxy which is dated last will be considered valid; if they are not dated or bear the same date without specific mention of time, all such multiple proxies will be treated as invalid.

**ATTENDANCE SLIP**

**PLEASE FILL ATTENDANCE SLIP AND HAND IT OVER AT THE ENTRANCE OF THE MEETING HALL**

**Joint shareholders may obtain additional slip at the venue of the Meeting**

<b>DP Id</b>	<b>Client Id</b>
<b>Regd. Folio No.*</b>	<b>No. of Shares</b>

<b>S. No.</b>	<b>Name in Full</b>	<b>Father's/ Husband Name</b>	<b>Address as Regd. With the Company</b>

I/we hereby record my/our presence at the Second Annual General Meeting of the Company held on Thursday, July 15, 2021 at 03:00 P.M. (IST) at the Registered Office of the Company


\_\_\_\_\_  
**Member's/ Proxy Signature\*\***

*\*Applicable for investors holding shares in physical form\**

*\*Please strike out whichever is not applicable*

1. Only Member/Proxyholder can attend the meeting.
2. Member/Proxyholder should bring his/her copy of the Annual Report to reference of the Meeting.

**ROUTE MAP TO REACH AT THE AGM VENUE**





## BOARD'S REPORT

Dear Members,

Your Directors have pleasure in presenting the 2<sup>nd</sup> Annual Report on the business and operations of Artemis Cardiac Care Private Limited ("**the Company**"), together with the audited financial statements for the financial year ended March 31, 2021.

### **FINANCIAL RESULTS**

The Company's financial performance for the financial year ended March 31, 2021 is summarised below:

*(₹ in Lacs)*

<b>Particulars</b>	<b>Year ended 31.03.2021</b>	<b>Year ended 31.03.2020</b>
Revenue from operation	639.47	192.90
Other Income	0.58	4.73
<b>Total Revenue</b>	<b>640.05</b>	<b>197.63</b>
Total Expenditure	778.00	359.21
<b>Profit before Tax</b>	<b>(137.95)</b>	<b>(161.58)</b>
Less: Tax Expense*	(44.86)	(36.81)
<b>Net Profit for the Year</b>	<b>(93.09)</b>	<b>(124.77)</b>

### **OPERATIONS AND FUTURE OUTLOOK**

The Revenue of the Company for the year ended March 31, 2021 amounted to ₹ 639.47 lacs as against ₹ 192.90 Lacs in the previous year. After providing for depreciation and tax, net loss amounted to ₹ 93.09 Lacs as against the loss of ₹ 124.77 in the previous year.

There is no amount proposed to be transferred to reserves during the year under review.

It is also pertinent to highlight that COVID 19 pandemic has resulted in disruption in regular business operation once again after second wave of COVID 19. However, the Company has adopted measures to ensure business continuity with minimal disruption and the business is expected to return to normal.

### **DIVIDEND**

The Board of Directors of your Company have not recommended any dividend for the year under review.

### **BOARD OF DIRECTORS AND KEY MANAGERIAL PERSONNEL**

There are no changes in the composition of the Board of Directors of the Company and hence, as at the end of financial year, the Composition of the Board of Directors were as under:

- i. Dr. Devlina Chakravarty
- ii. Dr. (Col) Manjinder Singh Sandhu
- iii. Mr. Sachin Grover

None of the aforesaid Directors are disqualified under Section 164(2) of the Companies Act, 2013 ("the Act").

In accordance with the provisions of the Act and the Articles of Association of the Company, Dr. (Col) Manjinder Singh Sandhu, Director of the Company, is liable to retire by rotation at the ensuing Annual General Meeting (AGM)., and being eligible, offers himself for re-

appointment. The Board recommended his re-appointment to the members at the ensuing AGM.

During the year under review, Mr. Rakesh Kumar Kaushik had stepped down from the position of Company Secretary of Holding Company from the close of business hours of October 21, 2020. As per the provisions of the Joint Venture Agreement between Artemis Medicare Services Limited and Philips Medical System Nederland B.V. dated November 09, 2018, the Company Secretary of the holding company shall be the Company Secretary of the subsidiary Company i.e. the Company. Ms. Shilpa Budhia, by virtue of being appointed as the Company Secretary and Compliance Officer of the holding Company was also appointed as Company Secretary of the Company on November 23, 2020.

#### **CHANGE IN NATURE OF BUSINESS, IF ANY**

During the year under review, there is no change in the nature of business of your Company.

#### **MATERIAL CHANGES AND COMMITMENTS**

Except the impact of COVID-19 as mentioned in hereinabove, no material changes and commitments affecting the financial position of your Company have occurred between the end of the financial year of the Company to which the financial statements relate and on the date of this report.

#### **SIGNIFICANT MATERIAL ORDERS PASSED BY REGULATORS**

No significant material orders have been passed during the year under review by the regulators or courts or tribunals impacting the going concern status and Company's operations in future.

#### **MEETINGS OF THE BOARD OF DIRECTORS**

The Board meets at regular intervals to discuss and decide on Company / business policy and strategy apart from other Board businesses. However, in case of a special and urgent business need, the Board's approval is taken by way of Board Meeting through shorter notice or by passing resolutions through circulation, as permitted by law, which are noted in the subsequent Board Meeting.

During the year under review, four (4) Board Meetings were convened and held. The intervening gap between the meetings was within the period as prescribed under the Act. The Board meetings were held on May 20, 2020, July 29, 2020, November 02, 2020 and February 02, 2021.

#### **CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO**

##### **A. Conservation of Energy**

##### **I. The steps taken or impact on conservation of energy**

The operations of the company are not energy-intensive. However, measures are being taken to reduce the energy consumption by using energy efficient equipment. Some of the efforts taken in the financial year under review are given as below:

- To create awareness among all users about energy conservation
- Energy consumption monitoring & controlling

As, energy costs comprises a very small part of Company's total expenses, the financial implications of these measures are not material.

## **B. Technology Absorption**

Efforts in brief, made towards technology absorption and benefits derived as a result of these efforts, e.g. product improvement, cost reduction, product development, import substitution etc.

Medical technology plays a crucial role in enhancing the quality of delivery, reduction in turnaround time of workflows and thus the overall cost, besides bringing in higher accountability into the system. Your Company has consistently invested in acquiring latest and newer technologies that result in better clinical outcomes and hence, greater patient satisfaction.

During the year under review, your Company has installed several new Cath Labs and other medical equipment to provide superior clinical outcomes to the patients. The above initiatives have helped the Company to provide improved medical quality and holistic care to our patients in a more effective manner.

## **C. FOREIGN EXCHANGE EARNING AND OUTGO**

Your Company is engaged in the healthcare business and is not carrying on any export business.

<b>Particulars</b>	<b>Current year</b>
1. Earnings in Foreign Currency	NIL
2. Expenditure in Foreign Currency	NIL

## **SUBSIDIARY/ HOLDING/ASSOCIATE COMPANIES**

Your company is the subsidiary Company of Artemis Medicare Services Limited.

## **PARTICULARS OF EMPLOYEES**

As required by Rule 5(2) and (3) of The Companies (Appointment and Remuneration of Managerial Personnel) Rules 2014, there were no employees employed during the year who were in receipt of remuneration which is not more than ₹ 8,50,000/- (Eight lacs fifty thousand only) per month or ₹ 1,02,00,000/- (One crore two lacs only) per annum.

## **DEPOSITS**

During the year under review, your Company did not accept deposits covered under Chapter V of the Act.

## **AUDITORS**

Pursuant to Section 139 of the Act, read with Companies (Audit and Auditors) Rules, 2014, the Company at its First AGM held on September 22, 2020, had appointed M/s. SCV & Co. LLP, Chartered Accountants (Firm Registration No.000235N/ N500089), as Statutory Auditors of your Company. The present term of M/s. SCV & Co. LLP, as Statutory Auditors, would expire at the conclusion of the 6<sup>th</sup> AGM.

## **AUDITORS REPORT**

The report given by M/s. SCV & Co. LLP, Chartered Accountants, Statutory Auditors on financial statements of the Company for FY 2020-21 is part of the Annual Report. The comments on statement of accounts referred to in the report of the Auditors are self-explanatory. The Auditors' Report does not contain any qualification, reservation or adverse remark. During the year under review, the Auditors had not reported any matter under

Section 143(12) of the Act. Therefore no detail is required to be disclosed under Section 134(3)(ca) of the Act.

### **REPORTING OF FRAUD**

During the year under review, the Auditors have not reported any fraud, which are committed against the Company by officers or employees of the Company.

### **PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE**

A formal policy is already in place for the prevention of sexual harassment of its employees at workplace and the Company has complied with provisions relating to the constitution of Internal Committee under the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013. During the year under review, no case was reported pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

### **SHARE CAPITAL**

#### **A. AUTHORISED CAPITAL**

The Authorized Capital of the Company is ₹15,00,00,000/- (Rupees Fifteen Crores only) divided into 1,50,00,000 (One Crore and Fifty Lacs only) equity shares of ₹10/- (Rupees ten only) each.

#### **B. PAID UP CAPITAL**

The Paid up Capital of the Company is ₹ 6,60,00,000/- (Rupees Six Crore and Sixty Lacs only) divided into 66,00,000 (Sixty-Six Lacs only) equity shares of ₹10/- (Rupees Ten only) each.

#### **C. CHANGES IN SHARE CAPITAL, IF ANY**

During the year under review, the Company has allotted 40,00,000 Equity shares in aggregate on right basis to existing shareholders as per below:

<b>Date</b>	<b>Allotment details</b>
October 22, 2020	20,00,000 Equity Shares of ₹ 10/- each
March 31, 2021	20,00,000 Equity Shares of ₹ 10/- each

#### **D. ISSUE OF EQUITY SHARES WITH DIFFERENTIAL RIGHTS**

Your Company has not issued any equity shares with differential rights during the year under review.

#### **E. PROVISION OF MONEY BY COMPANY FOR PURCHASE OF ITS OWN SHARES BY EMPLOYEES OR BY TRUSTEES FOR THE BENEFIT OF EMPLOYEES**

Your Company has not made any provision of money for purchase of its own shares by employees or by trustees for the benefit of employees during the year under review.

### **ANNUAL RETURN**

In terms of Section 92(3) of the Act and Rule 12 of the Companies (Management and Administration) Rules, 2014, the Annual Return of the Company is available on the website of the Company at the link: <https://www.artemiscardiac.com/>

### **PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS UNDER SECTION 186**

Pursuant to the requirements under Section 134(3) (g) of the Act, the Company has neither given any loans, guarantees nor made any investments under Section 186 of the Act.

### **RELATED PARTY TRANSACTIONS**

All arrangements/ transactions/ contracts entered by the Company during the financial year with related parties were in the ordinary course of business and on an arm's length basis and do not attract the provisions of Section 188 of the Act.

### **CORPORATE SOCIAL RESPONSIBILITY**

The provisions of Section 135 of the Act is not applicable to the Company.

### **CHANGE IN REGISTERED OFFICE OF THE COMPANY**

The Company continues to hold its registered office at Plot No. 14, Sector-20, Dwarka, New Delhi- 110075.

### **RISK MANAGEMENT**

The Company manages, monitors and reports on the principal risks and uncertainties that can impact its ability to achieve its strategic objectives. The Company has implemented Management System that incorporates framework for managing risks and internal controls. The Company's management systems, organizational structure, processes, standards and behaviours together form the Management System that governs how the Company conducts the business and manages associated risks.

The Company continues to integrate Risk Management, Internal Controls Management and Assurance frameworks and processes to drive a common integrated view of risks, optimal risk mitigation responses and efficient management of internal control and assurance activities. This integration is enabled by all three being fully aligned with Group level methodologies, processes and systems.

### **INTERNAL FINANCIAL CONTROLS**

Internal Financial Controls are an integrated part of the risk management process, addressing financial and financial reporting risks.

Assurance on the effectiveness of internal financial controls is obtained through management reviews, control self-assessment, continuous monitoring by functional experts as well as testing of the internal financial control systems by the statutory auditors during the course of their audits. The Company believes that these systems provide reasonable assurance that the Company's internal financial controls are designed effectively and are operating as intended.

### **DIRECTORS' RESPONSIBILITY STATEMENT**

Pursuant to the requirement under Section 134(5) of the Act, with respect to Directors' Responsibility Statement, the Directors confirm that:

- a) That in the preparation of the annual accounts, for the year ended March 31, 2021 the applicable accounting standards have been followed and no material departures have been made from the same;
- b) That they had selected such accounting policies and applied them consistently, and made judgments and estimates that are reasonable and prudent, so as to give a true

- and fair view of the state of affairs of the Company as at March 31, 2021 and of the profit and loss of the Company for that period;
- c) That they had taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
  - d) That they had prepared the annual accounts on a going concern basis; and
  - e) That they had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.
  - f) That they had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

#### **SECRETARIAL STANDARDS**

The Directors state that applicable Secretarial Standards, i.e., SS-1 and SS-2, relating to 'Meeting of the Board of Directors' and 'General Meetings', respectively, have been duly followed by the Company.

#### **ACKNOWLEDGEMENT**

Your Company upholds professionalism, integrity and continuous improvement across all functions, as well as optimum utilisation of the Company's resources for sustainable and profitable growth.

Your Directors wish to place on record their appreciation to business partners, members, bankers and other stakeholders for their continued support during the year. We also thank all our employees for their contributions towards the growth of your Company.

**For and on behalf of Board of Directors  
Artemis Cardiac Care Private Limited**

**Date: May 7, 2021  
Place: Gurugram**

**Sd/-  
Dr. Devlina Chakravarty  
Chairperson**

**Artemis Cardiac Care Private Limited**  
**Financial Statement for the year ended**  
**31st Mar, 2021**

## INDEPENDENT AUDITOR'S REPORT

TO THE MEMBERS OF  
**ARTEMIS CARDIAC CARE PRIVATE LIMITED**

### **Report on the Audit of the Ind AS Financial Statements**

#### **Opinion**

We have audited the accompanying Ind AS financial statements of **ARTEMIS CARDIAC CARE PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at 31st March, 2021, the Statement of Profit and Loss (including the Statement of Other Comprehensive Income), the Cash Flow Statements and the Statement of Changes in Equity for the year ended 31<sup>st</sup> March 2021, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information together referred to as "Ind AS financial statements".

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Ind AS financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31st March, 2021, and its loss including other comprehensive income, changes in equity and its cash flows and for the year ended on that date.

#### **Basis for Opinion**

We conducted our audit of the Ind AS financial statements in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Ind AS financial Statements' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Ind AS financial statements.

#### **Information other than the Ind AS financial Statements and Auditor's Report Thereon**

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Annual Report of the Board of Directors including annexures to Board's Report, but does not include the Ind AS financial statements and our auditor's report thereon.



In connection with our audit of the Standalone Ind AS financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### **Responsibilities of the Management and Those Charged with Governance for the Ind AS financial Statements**

The Company's Board of Directors is responsible for the matters stated in Section 134(5) of the Act with respect to the preparation of these Ind AS financial statements that give a true and fair view of the financial position, financial performance including other comprehensive income, changes in equity and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the Indian Accounting Standards (Ind AS) specified under section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Ind AS financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Ind AS financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's responsibility for the Audit of the Ind AS financial Statements**

Our objectives are to obtain reasonable assurance about whether the Ind AS financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Ind AS financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Ind AS financial statements, including the disclosures, and whether the Ind AS financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatement in the Ind AS financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Ind AS financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work ; and (ii) to evaluate the effect of any identified misstatement in the financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## Report on other legal and regulatory requirements

1. As required by the Companies (Auditor's Report) Order, 2016 ("the Order") issued by the Central Government of India in terms of sub-section (11) of Section 143 of the Act, we give in the "Annexure A", a statement on the matters specified in Paragraphs 3 and 4 of the Order.
2. As required by Section 143 (3) of the Act, we report that:
  - (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
  - (c) The Balance Sheet, the Statement of Profit and Loss (including other Comprehensive income), the Statement of Cash Flow and Statement of Changes in Equity dealt with by this Report are in agreement with the books of account.
  - (d) In our opinion, the aforesaid Ind AS financial statements comply with the Indian Accounting Standards specified under Section 133 of the Act, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended.
  - (e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
  - (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
  - (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended, in our opinion and to the best of our information and according to the explanations given to us:
    - i. The Company does not have any impact of pending litigations on its financial position in its financial statements.
    - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.

- iii. There were no amounts which were required to be transferred, to the Investor Education and Protection Fund by the Company.
3. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, as amended:

According to information and explanation given to us, no managerial remuneration for the year ended March 31, 2021 has been paid/provided by the Company to its directors in accordance with the provisions of section 197 read with Schedule V to the Act.

For SCV & Co. LLP  
CHARTERED ACCOUNTANTS  
FIRM REGISTRATION No. 000235N/N500089

PLACE: New Delhi  
DATED: 07<sup>th</sup> May, 2021

Sd/-  
( RAJIV PURI )  
PARTNER  
MEMBERSHIP No. 084318  
ICAI UDIN: 21084318AAAABF5077

## **Annexure “A” to the Independent Auditors’ Report**

**Annexure referred to in paragraph 1 under the heading “Report on other legal and regulatory requirements” of our Report of even date.**

- i. (a) The Company has maintained proper records showing full, including quantitative details and situation of fixed assets.
- (b) Fixed assets verification of the fixed assets has been conducted by the management during the year. All the fixed assets of the Company have not been physically verified by the management during the year but there is a regular phased programme of physical verification which, in our opinion, is reasonable having regard to the size of the Company and nature of its fixed assets. According to the information and explanations given to us, no material discrepancies were noticed on such verification.
- (c) The Company did not own any immovable property during the year
- ii. Physical verification of inventory has been conducted by the management at reasonable intervals during the year. The discrepancies noticed on verification between the physical stocks and book records, which in our opinion were not material, have been properly dealt with in the books of account.
- iii. According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has not granted any loans, secured or unsecured, to companies, firms, Limited Liability Partnerships or other parties covered in the register maintained under Section 189 of the Companies Act, 2013. Accordingly, the paragraphs 3(iii)(a), 3(iii)(b) and 3(iii)(c) of the Order are not applicable to the Company.
- iv. In our opinion and according to the information and explanations given to us there are no loans, investment, guarantees and securities granted in respect of which provisions of Sections 185 and 186 of the Companies Act, 2013 are applicable and hence not commented upon.
- v. According to the information and explanations provided by the management, we are of the opinion that the company has not accepted any deposits from public covered under section 73 to 76 or any other relevant provisions of the Companies Act, 2013 and rules framed there under. Accordingly, the paragraph 3(v) of the Order is not applicable to the Company.
- vi. The Companies (Cost Records and Audit) Rules, 2014 prescribed by Central Government under sub-section (1) of section 148 of the Companies Act, 2013 is not applicable to the Company.

- vii. (a) According to the information and explanations given to us and on the basis of our examination of the books of account, the Company has been generally regular in depositing undisputed statutory dues including provident fund, employees' state insurance, income-tax, goods and service tax, duty of custom, duty of excise, value added tax, cess and other material statutory dues applicable to it to the appropriate authorities.

According to the information and explanations given to us, no undisputed amounts payable in respect of provident fund, employees' state insurance, income tax, goods and service tax, duty of custom, duty of excise, value added tax and cess and other material statutory dues were outstanding, as on 31<sup>st</sup> March, 2021 for a period of more than six months from the date they became payable.

- (b) According to the information and explanations given to us, and on the basis of our examination of the books of account, there are no dues of income tax, goods and service tax, duty of custom, duty of excise, value added tax and cess which have not been deposited on account of any dispute.

- viii. Based on our audit procedures and on the information and explanations given to us, the Company has not defaulted in repayment of loans or borrowings to financial institutions or to any banks. The Company did not have any outstanding debentures, or loans or borrowings from Government during the year.

- ix. The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year. Based on our audit procedures and according to information and explanations given by the management, the term loans were applied for the purpose for which they were obtained.

- x. According to the information and explanations given to us, no fraud by the Company or no material fraud on the Company by its officers or employees has been noticed or reported during the year.

- xi. According to the information and explanations given to us and based on our examination of records of the Company, the Company has not paid or provided any managerial remuneration during the year. Accordingly, paragraph 3(xi) of the order is not applicable.

- xii. In our opinion and according to the information and explanations given to us, the Company is not a nidhi company. Accordingly, provisions of paragraph 3(xii) of the Order are not applicable to the Company.

- xiii. According to the information and explanations given to us and based on our examination of the records of the Company, transactions with the related parties are in compliance with sections 177 and 188 of the Companies Act, 2013 where applicable and details of such transactions have been disclosed in the Ind AS financial statements as required by the applicable accounting standards.

- xiv. According to the information and explanations give to us and based on our examination of the records of the Company, the Company has not made any preferential allotment or private placement

of shares or fully or partly convertible debentures during the year. Accordingly, provisions of paragraph 3(xiv) of the Order are not applicable to the Company.

- xv. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with him as referred to in section 192 of the Companies Act, 2013. Accordingly, provisions of paragraph 3(xv) of the Order are not applicable to the Company.
- xvi. The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act 1934. Accordingly, provisions of paragraph 3(xvi) of the Order are not applicable to the Company.

For SCV & Co. LLP  
CHARTERED ACCOUNTANTS  
FIRM REGISTRATION No. 000235N/N500089

PLACE: New Delhi  
DATED: 07<sup>th</sup> May, 2021

ICAI UDIN: 21084318AAAABF5077

Sd/-  
( RAJIV PURI )  
PARTNER  
MEMBERSHIP No. 084318

## **Annexure “B” To the Independent Auditor’s Report**

**Annexure referred to in paragraph 2(f) under the heading “Report on other legal and regulatory requirements” of our report of even date.**

### **Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)**

We have audited the internal financial controls over financial reporting of **ARTEMIS CARDIAC CARE PRIVATE LIMITED** (“the Company”) as of March 31, 2021 in conjunction with our audit of the Ind AS financial statements of the Company for the year ended on that date.

#### **Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

#### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by Institute of Chartered Accountants of India and deemed to be prescribed under section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected



depend on the auditor's judgement, including the assessment of the risks of material misstatement of the Ind AS financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of Ind AS financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorisations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls Over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For SCV & Co. LLP  
CHARTERED ACCOUNTANTS  
FIRM REGISTRATION No. 000235N/N500089

PLACE: New Delhi  
DATED: 07<sup>th</sup> May, 2021

Sd/-  
(RAJIV PURI )  
PARTNER  
MEMBERSHIP No. 084318  
ICAI UDIN: 21084318AAAABF5077

Artemis Cardiac Care Private Limited  
Balance Sheet as at 31st March, 2021

Particulars	Note No.	As at	As at
		31st March, 2021	31st March, 2020
		Rs. in Lacs	Rs. in Lacs
<b>Assets</b>			
<b>Non-current assets</b>			
Property, Plant and Equipment	2.1	1,128.85	614.44
Capital Work-in-Progress		5.26	-
Deferred Tax Assets (Net)	3	81.41	36.81
Non-Current Tax Assets (Net)	4	31.99	8.22
Other Non-Current Assets	5	0.95	0.09
<b>Total Non-Current Assets</b>	<b>A</b>	<b>1,248.46</b>	<b>659.56</b>
<b>Current Assets</b>			
Inventories	6	35.77	22.02
<b>Financial Assets</b>			
i. Trade Receivables	7	174.35	9.04
ii. Cash and Cash Equivalents	8	227.36	41.32
iii. Loans & Advances	9	0.74	0.77
iv. Other Financial Assets	10	0.80	1.08
Other Current Assets	5	4.42	1.76
<b>Total Current Assets</b>	<b>B</b>	<b>443.44</b>	<b>75.99</b>
<b>Total Assets</b>	<b>C = A + B</b>	<b>1,691.90</b>	<b>735.55</b>
<b>Equity and Liabilities</b>			
<b>Equity</b>			
Equity Share Capital	11	660.00	260.00
Other Equity	12	(217.20)	(124.77)
<b>Total Equity</b>	<b>D</b>	<b>442.80</b>	<b>135.23</b>
<b>Liabilities</b>			
<b>Non-Current Liabilities</b>			
<b>Financial Liabilities</b>			
i. Borrowings	13	896.30	500.66
Provisions	16	6.90	4.54
<b>Total Non-Current Liabilities</b>	<b>E</b>	<b>903.20</b>	<b>505.20</b>
<b>Current Liabilities</b>			
<b>Financial Liabilities</b>			
i. Borrowings	13	-	-
ii. Trade Payables	14	-	-
(A) Total Outstanding dues of Micro Enterprises and Small Enterprises		-	-
(B) Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises		141.12	58.06
iii. Other Financial Liabilities	15	192.46	29.05
Provisions	16	1.38	0.29
Other Current Liabilities	17	10.94	7.72
<b>Total Current Liabilities</b>	<b>F</b>	<b>345.90</b>	<b>95.12</b>
<b>Total Liabilities</b>	<b>G = E + F</b>	<b>1,249.10</b>	<b>600.32</b>
<b>Total Equity and Liabilities</b>	<b>H = D + G</b>	<b>1,691.90</b>	<b>735.55</b>

Significant Accounting Policies 1.2  
See accompanying Notes to Financial Statements 2 to 36

As per our report of even date attached  
For SCV & Co. LLP  
Chartered Accountants  
Firm Registration Number 000235N / N500089

For and on behalf of the Board of Directors  
of Artemis Cardiac Care Private Limited

SD/-  
(Rajiv Puri)  
Partner  
Membership No. 084318

SD/-  
Dr. Devlina Chakravarty  
[Director]  
[DIN : 07107875]

SD/-  
Dr. MS Sandhu  
[Director]  
[DIN : 08409644]

Place : New Delhi  
Dated: 7th May 2021

SD/-  
Arpit Jain  
[CEO]

SD/-  
Shilpa Budhia  
[Company Secretary]

Place : Gurugram  
Dated: 7th May 2021

**Artemis Cardiac Care Private Limited**  
**Statement of Profit & Loss for the year ended 31st March 2021**

Particulars	Note No.	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>Income</b>			
Revenue from Operations	18	639.47	192.90
Other Income	19	0.58	4.73
<b>Total Income</b>	<b>( I )</b>	<b>640.05</b>	<b>197.63</b>
<b>Expenses</b>			
Purchases of Pharmacy Drugs & Medical Consumables		176.76	88.33
Changes in Inventories	20	(13.75)	(22.02)
Employee Benefits Expense	21	150.36	115.14
Finance Costs	22	66.96	29.30
Depreciation and Amortization Expense	23	86.55	30.27
Other Expenses	24	311.12	118.19
<b>Total Expenses</b>	<b>( II )</b>	<b>778.00</b>	<b>359.21</b>
<b>Profit Before Tax</b>	<b>III = ( I - II )</b>	<b>(137.95)</b>	<b>(161.58)</b>
<b>Tax Expense</b>			
Tax Expense	25		
Current Tax		-	-
Deferred Tax		(44.86)	(36.81)
<b>Total Tax Expense</b>	<b>( IV )</b>	<b>(44.86)</b>	<b>(36.81)</b>
<b>Profit After Tax</b>	<b>V = ( III - IV )</b>	<b>(93.09)</b>	<b>(124.77)</b>
<b>Other Comprehensive Income for the year</b>			
Items that will not be reclassified to profit or loss	VI		
Remeasurement of defined employee benefit plans (Refer note 29)		0.92	-
Income tax relating to items that will not be reclassified to profit or loss		(0.26)	-
<b>Other Comprehensive Income</b>	<b>VI</b>	<b>0.66</b>	<b>-</b>
<b>Total Comprehensive Income</b>	<b>VII= (V+VI)</b>	<b>(92.43)</b>	<b>(124.77)</b>
<b>Earning Per Equity Share (Face Value Of Rs. 10/- Each)</b>			
<b>Basic(Rs.)</b>	27	(2.66)	(6.86)
<b>Diluted(Rs.)</b>		(2.66)	(6.86)
Significant Accounting Policies	1.2		
See accompanying Notes to Financial Statements	2 to 36		

For SCV & Co. LLP  
Chartered Accountants  
Firm Registration Number 000235N / N500089

For and on behalf of the Board of Directors  
of Artemis Cardiac Care Private Limited

SD/-  
(Rajiv Puri)  
Partner  
Membership No. 084318

SD/-  
Dr. Devlina Chakravarty  
[Director]  
[DIN : 07107875]

SD/-  
Dr. MS Sandhu  
[Director]  
[DIN : 08409644]

Place : New Delhi  
Dated: 7th May 2021

SD/-  
Arpit Jain  
[CEO]

SD/-  
Shilpa Budhia  
[Company Secretary]

Place : Gurugram  
Dated: 7th May 2021

Artemis Cardiac Care Private Limited  
Cash Flow Statement for the year ended 31st March 2021

Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>Cash flow from operating activities</b>		
Profit before tax	(137.95)	(161.58)
<b>Adjustments:</b>		
Depreciation and amortisation	86.55	30.27
Interest Income	(0.31)	(4.49)
Finance Cost	66.96	29.30
Loss on sale/scrap of Property, Plant and Equipment	4.57	-
<b>Operating cash flow before working capital changes</b>	<b>19.82</b>	<b>(106.50)</b>
<b>Movements in working capital :</b>		
Changes in trade receivables	(165.32)	(9.04)
Changes in inventories	(13.75)	(22.02)
Changes in loans(Current)	0.03	(0.77)
Changes in other non current assets	(0.86)	(0.09)
Changes in other financial assets (Current)	0.28	(1.08)
Changes in other current assets	(2.66)	(1.76)
Changes in trade payables	83.06	58.06
Changes in provisions(Non Current)	4.37	4.54
Changes in Other current liabilities(Current)	3.22	4.01
Changes in Other financial liabilities(Current)	92.84	33.04
<b>Cash generated from operations</b>	<b>21.04</b>	<b>(41.60)</b>
Income tax paid/(refund)	(23.77)	(8.22)
<b>Net cash generated from operating activities (A)</b>	<b>(2.73)</b>	<b>(49.82)</b>
<b>Cash flow from investing activity</b>		
Purchase of Property, Plant & Equipment	(623.87)	(644.71)
Proceeds from sale of Property, Plant & Equipment	13.08	-
Interest received	0.31	4.49
<b>Net cash (used in) investing activities (B)</b>	<b>(610.48)</b>	<b>(640.22)</b>
<b>Cash flow from financing activity</b>		
Proceeds from long term borrowings	466.20	507.00
Repayment of long term borrowings	-	(6.34)
Proceeds from issue of Equity share capital	400.00	260.00
Interest paid	(66.96)	(29.30)
<b>Net cash generated from financing activities (C)</b>	<b>799.25</b>	<b>731.36</b>
<b>Net increase in cash &amp; cash equivalents (A+B+C)</b>	<b>186.04</b>	<b>41.32</b>
<b>Cash &amp; cash equivalents at the beginning of the year</b>	<b>41.32</b>	<b>-</b>
<b>Cash &amp; cash equivalents at the end of the year</b>	<b>227.36</b>	<b>41.32</b>
<b>Components of cash and cash equivalents</b>		
Cash on hand	0.46	0.46
Balances with Banks:		
in current accounts	226.90	40.86
<b>Total</b>	<b>227.36</b>	<b>41.32</b>

As per our report of even date attached  
For SCV & Co. LLP  
Chartered Accountants  
Firm Registration Number 000235N / N500089

SD/-  
(Rajiv Puri)  
Partner  
Membership No. 084318

Place : New Delhi  
Dated: 7th May 2021

For and on behalf of the Board of Directors  
of Artemis Cardiac Care Private Limited

SD/-  
Dr. Devlina Chakravarty  
[Director]  
[DIN : 07107875]

SD/-  
Dr. MS Sandhu  
[Director]  
[DIN : 08409644]

SD/-  
Arpit Jain  
[CEO]

SD/-  
Shilpa Budhia  
[Company Secretary]

Place : Gurugram  
Dated: 7th May 2021

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No. 2.1

Rs in Lacs

**Property, Plant and Equipment**

Particulars	Computers	Furniture & Fixtures	Office Equipments	Plant and Equipments	Vehicles	Total
<b>Gross Block</b>						
Additions during the period	6.26	7.89	6.59	612.89	11.08	644.71
Disposals / Discarded during the period	-	-	-	-	-	-
Adjustment during the period	-	-	-	-	-	-
<b>As at 31st March 2020</b>	<b>6.26</b>	<b>7.89</b>	<b>6.59</b>	<b>612.89</b>	<b>11.08</b>	<b>644.71</b>
Additions during the year	2.08	19.55	2.33	594.65	-	618.61
Disposals / Discarded during the year	-	(1.67)	-	(18.10)	-	(19.77)
Adjustment during the year	-	-	-	-	-	-
<b>As at 31st March, 2021</b>	<b>8.34</b>	<b>25.77</b>	<b>8.92</b>	<b>1,189.44</b>	<b>11.08</b>	<b>1,243.55</b>
<b>Accumulated Depreciation</b>						
Charge for the period	1.38	1.02	0.30	26.46	1.11	30.27
Disposals / Discarded during the period	-	-	-	-	-	-
<b>As at 31st March 2020</b>	<b>1.38</b>	<b>1.02</b>	<b>0.30</b>	<b>26.46</b>	<b>1.11</b>	<b>30.27</b>
Charge for the year	2.39	3.14	1.89	77.74	1.39	86.55
Disposals / Discarded during the year	-	(0.20)	-	(1.92)	-	(2.12)
<b>As at 31st March, 2021</b>	<b>3.77</b>	<b>3.96</b>	<b>2.19</b>	<b>102.28</b>	<b>2.50</b>	<b>114.70</b>
<b>Net Block</b>						
<b>As at 31st March 2020</b>	<b>4.88</b>	<b>6.87</b>	<b>6.29</b>	<b>586.43</b>	<b>9.97</b>	<b>614.44</b>
<b>As at 31st March, 2021</b>	<b>4.57</b>	<b>21.81</b>	<b>6.73</b>	<b>1,087.16</b>	<b>8.58</b>	<b>1,128.85</b>

Note No.	Deferred tax assets / (liabilities) in relation to :	As at 31st March, 2020	Credit / (Charge) to Profit or loss	Credit / (Charge) to Other Comprehensive Income	As at 31st March, 2021
<b>3</b>	<b>Deferred Tax Assets / (Liabilities) (Net)</b> The following is the analysis of deferred tax assets / liabilities recognised in statement of profit and loss and Other Comprehensive Income				
	Property, plant and equipment	(11.00)	(8.73)	-	(19.73)
	Employee Benefits	1.22	1.34	(0.26)	2.30
	Unabsorbed business losses as per Income Tax Act	46.41	52.37	-	98.78
	Others	0.18	(0.12)	-	0.06
		<u>36.81</u>	<u>44.86</u>	<u>(0.26)</u>	<u>81.41</u>

Note: Deferred tax assets and deferred tax liabilities have been offset as they are governed by the same taxation laws.

Note No.	Deferred tax assets / (liabilities) in relation to :	Credit / (Charge) to Profit or loss	Credit / (Charge) to Other Comprehensive Income	As at 31st March, 2020
<b>3</b>	<b>Deferred Tax Assets / (Liabilities) (Net)</b> The following is the analysis of deferred tax assets / liabilities recognised in statement of profit and loss and Other Comprehensive Income			
	Property, plant and equipment	(11.00)		(11.00)
	Employee Benefits	1.22		1.22
	Unabsorbed business losses as per Income Tax Act	46.41		46.41
	Others	0.18		0.18
		<u>36.81</u>		<u>36.81</u>

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>4</b>	<b>Income tax assets</b>		
	<b>Non Current</b>		
	Income Tax Recoverable	31.99	8.22
	<b>Total</b>	<u>31.99</u>	<u>8.22</u>

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>5</b>	<b>Other Assets</b>		
	(Unsecured, Considered good)		
	<b>Non-Current</b>		
	Capital Advances	0.95	-
	Prepaid Expenses	-	0.09
	<b>Total</b>	<u>0.95</u>	<u>0.09</u>
	<b>Current</b>		
	(Unsecured, Considered good)		
	Advances recoverable	2.53	1.00
	Balance with statutory authorities	1.05	0.32
	Prepaid Expenses	0.84	0.44
	<b>Total</b>	<u>4.42</u>	<u>1.76</u>

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>6</b>	<b>Inventories</b>		
	(Valued at lower of cost or net realisable value)		
	Stock of Pharmacy Drugs & Medical Consumables	35.77	22.02
	<b>Total</b>	<u>35.77</u>	<u>22.02</u>

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>7</b>	<b>Trade Receivables (Unsecured)</b>		
	<b>Current</b>		
	Considered good	174.35	9.04
	<b>Total</b>	<u>174.35</u>	<u>9.04</u>

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

<b>Note No</b>	<b>Particulars</b>	<b>As at 31st March, 2021 Rs. In Lacs</b>	<b>As at 31st March, 2020 Rs. In Lacs</b>
<b>8</b>	<b>Cash &amp; Cash Equivalent</b>		
	<b>Balance with Banks:</b>		
	- In Current Accounts	226.90	40.86
	Cash on hand	0.46	0.46
		<b>227.36</b>	<b>41.32</b>

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>9</b>	<b>Loans</b>		
	<b><u>Current</u></b> (Unsecured, Considered good)		
	Security Deposits	-	0.21
	<b>Others</b>		
	Loans & advances to Employees	0.74	0.56
		<b>0.74</b>	<b>0.77</b>
		<hr/> <hr/>	<hr/> <hr/>
Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>10</b>	<b>Other Financial Assets</b>		
	<b>Current</b>		
	Unbilled Revenue(Accrued operating income)	0.80	1.08
		<b>0.80</b>	<b>1.08</b>
		<hr/> <hr/>	<hr/> <hr/>



Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	As at	As at
		31st March, 2021 Rs. In Lacs	31st March, 2020 Rs. In Lacs
11	<b>Equity Share Capital:</b>		
	Authorised Shares (in nos.) 1,50,00,000 Equity Shares of Rs. 10/- each	1,500.00	1,500.00
	Issued, Subscribed & Paid Up Shares (in nos.)  66,00,000 (Previous Year:26,00,000 )Equity Shares of Rs. 10/- each	660.00	260.00
	<b>Total issued, subscribed and fully paid up capital</b>	<b>660.00</b>	<b>260.00</b>

a. Reconciliation of the equity shares at the beginning and at the end of the year

Reconciliation	As at 31st March, 2021		As at 31st March, 2020	
	Nos.	Rs. In Lacs	Nos.	Rs. In Lacs
Shares outstanding at the beginning of the year	26,00,000	260.00	-	-
Shares issued during the year/period	40,00,000	400.00	26,00,000	260.00
Shares bought back during the year	-	-	-	-
<b>Shares outstanding at the end of the year</b>	<b>66,00,000</b>	<b>660.00</b>	<b>26,00,000</b>	<b>260.00</b>

b. Terms/rights attached to Equity Shares

The company has only one class of equity shares having a par value of Rs. 10 per share. Each holder of equity shares is entitled to one vote per share, where voting is held by show of hands. In case of Poll each holder of equity share is entitled to Number of votes against Number of shares held.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the equity share holders.

c. Equity Shares held by holding company :

Name of the Shareholder	As at 31st March 2021		As at 31st March 2020	
	No. of Shares	Rs. In Lacs	No. of Shares	Rs. In Lacs
Artemis Medicare Services Limited - holding company	42,90,000	429.00	16,90,000	169.00

d. Details of Shareholders holding more than 5% Equity Shares in the Company:

Name of the Shareholder	As at 31st March 2021		As at 31st March 2020	
	No. of Shares	% of Holding	No. of Shares	% of Holding
Artemis Medicare Services Limited - holding company	42,90,000	65%	16,90,000	65%
Philips Medical Systems Nederland BV	23,10,000	35%	9,10,000	35%

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>12</b>	<b>Other Equity:</b>		
	<b>Retained earnings</b>		
	Balance as per last financial statements	(124.77)	-
	Profit / (Loss) for the year/period	(93.09)	(124.77)
	Other comprehensive income arising from re-measurement of defined benefit obligation net of income tax	0.66	-
	<b>Balance at end of the year</b>	<b>(217.20)</b>	<b>(124.77)</b>
	<b>Total Other Equity</b>	<b>(217.20)</b>	<b>(124.77)</b>

**Retained Earnings**

Retained earnings represents the profits that the Company has earned till date, less any transfer to general reserve and dividends or other distributions to shareholders etc.

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Statement of changes in Equity

1) Equity Share Capital

Particulars	Note	Amount
Equity Share capital issued during the period	11	260.00
<b>Balance as at March 31, 2020</b>	<b>11</b>	<b>260.00</b>
Changes in equity share capital during the year	11	400.00
<b>Balance as at March 31, 2021</b>	<b>11</b>	<b>660.00</b>

2) Other Equity

Particulars	Note No.	Reserve & Surplus Retained Earnings	Items of OCI Remeasurements of the net defined benefit plans	Total
Profit/ (Loss) for the period	12	(124.77)	-	(124.77)
Other Comprehensive Income (OCI) (net of tax)	12	-	-	-
<b>Balance as at March 31, 2020</b>	<b>12</b>	<b>(124.77)</b>	<b>-</b>	<b>(124.77)</b>
Profit/ (Loss) for the year	12	(93.09)	-	(93.09)
Other Comprehensive Income (OCI) (net of tax)	12	-	0.66	0.66
<b>Balance as at March 31, 2021</b>	<b>12</b>	<b>(217.86)</b>	<b>0.66</b>	<b>(217.20)</b>

Significant Accounting Policies  
See accompanying Notes to Financial Statements

1.2  
2 to 36

As per our report of even date attached  
For SCV & Co. LLP  
Chartered Accountants  
Firm Registration Number 000235N / N500089

For and on behalf of the Board of Directors  
of Artemis Cardiac Care Private Limited

SD/-  
(Rajiv Puri)  
Partner  
Membership No. 084318

SD/-  
Dr. Devlina Chakravarty  
[Director]  
[DIN : 07107875]

SD/-  
Dr. MS Sandhu  
[Director]  
[DIN : 08409644]

Place : New Delhi  
Dated: 7th May 2021

SD/-  
Arpit Jain  
[CEO]

SD/-  
Shilpa Budhia  
[Company Secretary]

Place : Gurugram  
Dated: 7th May 2021

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>13</b>	<b>Borrowings</b>		
	<b>Non Current</b>		
	<b>Term Loans</b>		
	<u>From Banks</u>		
	- Indian Rupee loans from Banks (secured at amortised cost)	896.30	500.66
	<b>Total</b>	<b>896.30</b>	<b>500.66</b>
	<b>Current Maturity</b>		
	<b>Term Loans</b>		
	<u>From Banks</u>		
	- Indian Rupee loans from Banks (secured)	70.57	-
		<b>70.57</b>	<b>-</b>
	Transferred to Other Financial Liability (Note 15)	(70.57)	-
	<b>Total</b>	<b>-</b>	<b>-</b>

**1. Indian Rupee Loans from Banks include :**

- a) Term loans of Rs. 966.87 Lacs (As at 31st March, 2020 Rs. 500.66 Lacs) from Scheduled Bank carries interest as linked with one year MCLR plus spread of 0.95%. The loans are secured by the charge on entire movable fixed assets and second charge on current assets. Further, these loans are secured by corporate guarantee given by holding company.

Repayment Schedule	Secured Loan- HDFC Bank
FY 2021-22	70.57
FY 2022-23	173.04
FY 2023-24	192.27
FY 2024-25	201.88
FY 2025-26	211.50
FY 2026-27	117.61
<b>Total</b>	<b>966.87</b>

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>14</b>	<b>Trade payables</b>		
	Total Outstanding dues of Micro Enterprises and Small Enterprises (Refer Note 28)	-	-
	Total Outstanding dues of Creditors other than Micro Enterprises and Small Enterprises	141.12	58.06
	<b>Total</b>	<b>141.12</b>	<b>58.06</b>
<b>15</b>	<b>Other Financial Liabilities</b>		
	<b>Current</b>		
	Term Loan (current maturity)-Refer Note 13	70.57	-
		<b>70.57</b>	<b>-</b>
	Interest Accrued but not due on borrowings	6.80	4.01
	Other Payable*	115.09	25.04
	<b>Total</b>	<b>192.46</b>	<b>29.05</b>

\* Other payable includes payments due on account of capital items, due to employees.

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>16</b>	<b>Provisions</b>		
	<b><u>Non- Current</u></b>		
	<b>Provision for Employee Benefits</b>		
	Leave Benefits	5.85	3.29
	Gratuity (Refer Note 29)	1.05	1.25
	<b>Total</b>	<b>6.90</b>	<b>4.54</b>
	<b><u>Current</u></b>		
	<b>Provision for Employee Benefits</b>		
	Leave Benefits	1.38	0.29
	Gratuity * (Refer Note 29)	0.00	0.00
	<b>Total</b>	<b>1.38</b>	<b>0.29</b>

\* The figure is below rounding off norms( Rs. 391, 31st March 2021; Rs. 202, 31st March 2020)

Note No.	Particulars	As at 31st March, 2021 Rs. In Lacs	As at 31st March, 2020 Rs. In Lacs
<b>17</b>	<b>Other Liabilities</b>		
	<b>Current</b>		
	Security Deposits	2.52	3.37
	Taxes and other statutory dues*	8.42	4.35
	<b>Total</b>	<b>10.94</b>	<b>7.72</b>

\*Taxes and other statutory dues includes Withholding Tax, Goods and Services Tax contribution of PF, ESI etc.

Artemis Cardiac Care Private Limited  
Notes to Financial Statements for the year ended 31st March, 2021

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>18</b>	<b>Revenue from Operations</b>		
	<b>Sale of Services</b>		
	Revenue from Health Care Services	510.07	152.93
	<b>Sale of Goods</b>		
	Sale of Pharmacy Drugs & Medical Consumables	129.40	39.97
	<b>Total</b>	<b>639.47</b>	<b>192.90</b>

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>19</b>	<b>Other Income</b>		
	Interest Income		
	- From Bank deposits	0.31	4.49
	Other Non-Operating Income	0.27	0.24
	<b>Total</b>	<b>0.58</b>	<b>4.73</b>

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>20</b>	<b>(Increase) / Decrease in Inventories of Pharmacy Drugs &amp; Medical Consumables</b>		
	Inventories at the beginning of the year	22.02	-
	Inventories at the end of the year	35.77	(13.75)
	<b>Total</b>	<b>(13.75)</b>	<b>(22.02)</b>

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>21</b>	<b>Employee Benefits Expense</b>		
	Salaries, Wages and Bonus	137.55	109.19
	Contribution to Provident and Other Funds	8.14	3.88
	Gratuity Expenses(Refer Note 29)	0.73	1.25
	Employee Welfare Expenses	3.94	0.82
	<b>Total</b>	<b>150.36</b>	<b>115.14</b>

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>22</b>	<b>Finance Costs</b>		
	Interest expense on financial liabilities measured at amortised cost		
	- On term Loans	65.03	26.92
	Other Borrowing Costs	0.63	0.48
	Bank Charges	1.30	1.90
	<b>Total</b>	<b>66.96</b>	<b>29.30</b>

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>23</b>	<b>Depreciation and amortization expense</b>		
	Depreciation of property, plant and equipment	86.55	30.27
	<b>Total</b>	<b>86.55</b>	<b>30.27</b>

**Artemis Cardiac Care Private Limited**  
**Notes to Financial Statements for the year ended 31st March, 2021**

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the year ended 31st March, 2020 Rs. in Lacs
<b>24</b>	<b>Other expenses</b>		
	Rent - Lease Rent	1.28	1.42
	Legal & Professional Fees	2.43	4.35
	Equipment Hire Charges	0.48	-
	Patient Facility Maintenance	11.22	6.86
	Patient Food & Beverages Expenses	0.25	0.19
	Preliminary Expenses Written Off	-	15.60
	Travelling & Conveyance	6.60	11.52
	Advertisement & Business Promotion	18.31	10.02
	Professional Medical Consultancy	5.91	3.78
	Auditors Remuneration		
	- Statutory Audit Fee	1.18	1.18
	-Tax Audit Fee	0.59	0.50
	- Others Services & Certification	0.89	1.36
	Printing & Stationery	0.85	0.85
	Communication Expenses	2.67	1.86
	Outsource Lab Test Charges	1.17	1.42
	Security Charges	4.00	1.93
	Fee paid to doctors	193.53	41.02
	Power & Fuel	11.50	5.87
	Repairs and Maintenance		
	- Machinery	27.85	1.44
	- Others	1.41	5.78
	Insurance	0.91	0.23
	Rates & Taxes	13.30	0.55
	Subscription / Membership Fees	0.15	0.22
	Loss on Sale / Scrap of Property, Plant and Equipment (Net)	4.57	-
	Miscellaneous Expenses	0.07	0.24
	<b>Total</b>	<b>311.12</b>	<b>118.19</b>



**Artemis Cardiac Care Private Limited**  
**Notes to Financial Statements for the year ended 31st March, 2021**

**INCOME TAX**

Note No.	Particulars	For the year ended 31st March, 2021 Rs. in Lacs	For the period ended 31st March, 2020 Rs. in Lacs
<b>25</b>	<b>Amount recognised in Statement of Profit &amp; Loss</b>		
	<b>Current Tax</b>		
	(a) In respect of the current year		
	(b) Earlier years tax provision written back		
	<b>Deferred Tax</b>		
	(a) In respect of the current year	(44.86)	(36.81)
	<b>Tax expense recognised through statement of profit and loss</b>	<b>(44.86)</b>	<b>(36.81)</b>
	<b>Recognised in Other Comprehensive Income (OCI)</b>		
	<b>Deferred tax</b>		
	In respect of the current year	(0.26)	-
	<b>Tax credit recognised through Other Comprehensive Income</b>	<b>(0.26)</b>	<b>-</b>
	The income tax expense for the year can be reconciled to the accounting profit as follows:		
	Profit before tax	(137.95)	(161.58)
	Enacted income tax rate in India	27.82%	27.82%
	Income tax calculated	(38.38)	(44.95)
	Others	(6.48)	8.14
	<b>Income tax expense recognised in statement of profit &amp; loss</b>	<b>(44.86)</b>	<b>(36.81)</b>

**Artemis Cardiac Care Private Limited**  
**Notes to Financial Statements for the year ended 31st March, 2021**

**Note**  
**No.**

**1.1 Nature of operations**

Artemis Cardiac Care Private Limited ("The Company") was incorporated on 14th Jan, 2019 with an object of developing, operating and managing multiple cardiac centres with interventional & diagnostics cardiology and critical care capability in private and public hospitals.

**1.2 Statement of Significant Accounting Policies**

**a) Statement of compliance**

The financial statements have been prepared in accordance of Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act 2013 (the "Act") read together with Companies (Indian Accounting Standard) Rules, 2015 as amended  
The financial statements were approved by the Company's Board of Directors on 7th May, 2021.

**b) Basis of preparation and presentation**

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Historical Cost is generally based on the fair value of the consideration given in exchange of goods and services.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company taken into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and / or disclosure purposes in these financial statements is determined on such a basis.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2, or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the assets or liabilities either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

**c) Property, Plant and Equipment (PPE)**

Property, Plant and Equipment are stated at cost (or revalued amounts, as the case may be), less accumulated depreciation and impairment loss, if any. Cost comprises the purchase price and any attributable cost of bringing the property, plant and equipment to its working condition for its intended use. Borrowing costs relating to acquisition of property, plant and equipment which takes substantial period of time to get ready for its intended use are also included to the extent they relate to the period till such property, plant and equipment are ready to be put to use.

The cost of an item of property, plant and equipment is the case price equivalent at the recognition date. If payment is deferred beyond normal credit terms, the difference between the cash price equivalent and the total payment is recognised as interest over the period of credit, unless such interest is capitalised as per borrowing cost.

The Company identifies and determines separate useful life of each major component of the property, plant and equipment, if they have useful life that is materially different from that of the remaining asset, as per Schedule II of Companies Act, 2013.

**d) Depreciation on Property, Plant and Equipment**

Depreciation on all of the property, plant and equipment on the cost of assets less their residual values on straight line method over the useful lives as indicated in Part C of Schedule II of the Companies Act, 2013. Depreciation Methods, useful lives and residual values are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis

Depreciation commences when the fixed assets are ready for their intended use. Depreciation is provided on a straight line based on the estimated useful life of PPE as per management internal assessment, which is as follows:

<b>Assets</b>	<b>Useful Life as per Schedule II</b>
Plant & Machinery	7-15 Years
Office Equipments	5 Years
Computers	3 Years
Furnitures & Fittings	10 Years
Vehicles	8 Years

**e) Intangible Assets**

Intangible assets acquired separately are measured on initial recognition at cost less accumulated amortisation and accumulated impairment losses, if any.

Cost is the amount of cash or cash equivalents paid or the fair value of other consideration given to acquire an asset at the time of its acquisition or construction, or, when applicable, the amount attributed to that asset when initially recognised in accordance with the specific requirements of other Indian Accounting Standards.

## **f) Leases**

### **Where the Company is the lessee**

The Company's lease asset classes primarily consist of leases for buildings. The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (i) the contract involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset.

At the date of commencement of the lease, the Company recognizes a right-of-use asset ("ROU") and a corresponding lease liability for all lease arrangements in which it is a lessee, except for leases with a term of twelve months or less (short-term leases) and low value leases. For these short-term and low value leases, the Company recognizes the lease payments as an operating expense on a straight-line basis over the term of the lease.

Certain lease arrangements include the options to extend or terminate the lease before the end of the lease term. ROU assets and lease liabilities include these options when it is reasonably certain that they will be exercised.

The right-of-use assets are initially recognized at cost, which comprises the initial amount of the lease liability adjusted for any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. Right of use assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates. Lease liabilities are remeasured with a corresponding adjustment to the related right of use asset if the Company changes its assessment of whether it will exercise an extension or a termination option. Lease liability and ROU asset have been separately presented in the Balance Sheet and lease payments have been classified as financing cost.

### **Where the Company is the lessor**

Leases for which the Company is a lessor is classified as a finance or operating lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

Assets subject to operating leases are included in PPE. Rental income on operating lease is recognized in the statement of profit and loss on a straight-line basis over the lease term. Where the rentals are structured solely to increase in line with expected general inflation to compensate for the Company's expected inflationary cost increases, such increases are recognized in the year in which such benefits accrue.

Costs, including depreciation, are recognized as an expense in the statement of profit and loss. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased assets and recognised on a straight line basis over the lease term.

## **g) Inventories**

Inventories consisting of pharmacy drugs and medical consumables are measured at the lower of cost and net realisable value. The cost of all categories of inventories is based on the Weighted Average Cost method.

Net realizable value is the estimated selling price in the ordinary course of business, less estimated costs necessary to make the sale.

## **h) Revenue recognition**

Revenue is measured at the transaction price. Revenue is reduced for returns, trade allowances for deduction, rebates, taxes and amounts collected on behalf of third parties.

The Company applies the revenue recognition criteria to each separately identifiable component of the Revenue transaction as set out below:

### Sale of Pharmacy Drugs and Medical supplies

Revenue from the sale of pharmacy drugs and medical supplies is recognised, at a point of time when the control of the goods has passed to the buyer i.e. at the point of sale/ delivery to the customer at an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods. Sale is net of sales returns, discounts & Goods & Services Tax.

### Income from Operations

Revenue is recorded when the performance obligation is satisfied. For Out Patient Customer, services are simultaneously received and consumed by the patient. For In patient customers, revenue is recognized as services are performed over the period. Revenue for the ongoing services at the reporting date is recognized as unbilled revenue. The income is stated net of discounts and price differences as per the terms of contract.

### Interest

Interest income is recognised on a time proportion basis taking into account the amount outstanding and the applicable interest rate.

## **i) Employees Benefits**

### **Short term employee benefits**

Employee benefits payable wholly within twelve months of receiving services are classified as short-term employee benefits. These benefits include salary and wages, bonus and exgratia. The undiscounted amount of short-term employee benefits to be paid in exchange for employee services is recognized as an expense as the related service is rendered by the employees.

### **Post employment benefits**

#### Defined contribution plans

A defined contribution plan is post-employment benefit plan under which an entity pays specified contributions to separate entity and has no obligation to pay any further amounts. The Company makes specified obligations towards employee provident fund and employee state insurance to Government administered provident fund scheme and ESI scheme which is a defined contribution plan. The Company's contributions are recognized as an expense in the statement of profit and loss during the period in which the employee renders the related service.

#### Defined benefit plans

The Company's gratuity benefit scheme is a defined benefit plan. The Company's net obligation in respect of a defined benefit plan is calculated by estimating the amount of future benefit that employees have earned and returned for services in the current and prior periods; that benefit is discounted to determine its present value. The calculation of Company's obligation under the plan is performed periodically by a qualified actuary using the projected unit credit method.

When the benefits of a plan are changed or when a plan is curtailed, the resulting change in benefit that relates to past service or the gain or loss on curtailment is recognised immediately in the statement of profit and loss.

#### Compensated absences

The employees can carry-forward a portion of the unutilized accrued compensated absences and utilize it in future service periods. The Company records an obligation for such compensated absences in the period in which the employee renders the services that increase this entitlement. The obligation is measured on the basis of independent actuarial valuation using the projected unit credit method.

## **j) Income taxes**

**Income tax expense represents the sum of the tax currently payable and deferred tax.**

### *i) Current Tax*

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The current tax is calculated using tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period.

Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961 enacted in India and tax laws prevailing in the respective tax jurisdictions where the Group operates.

### *ii) Deferred tax*

Deferred tax is recognized on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in computation of taxable profit.

Deferred tax liabilities are generally recognized for all taxable temporary differences. Deferred tax assets are generally recognized for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilized.

Deferred tax is measured based on tax rates and tax laws enacted or substantively enacted at the balance sheet date. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities. Deferred tax assets are recognized only to the extent, that there is reasonable certainty that sufficient future taxable income will be available against which such deferred tax assets can be realized. In situations where the company has unabsorbed depreciation or carry forward tax losses, all deferred tax assets are recognized only if there is virtual certainty supported by convincing evidence that they can be realized against future taxable profits.

The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that is no longer probable that sufficient taxable profits will be available to allow all part of assets to be recovered.

Deferred tax is measured based on tax rates and tax laws enacted or substantively enacted by the end of the reporting period. Deferred tax assets and deferred tax liabilities are offset, if a legally enforceable right exists to set off current tax assets against current tax liabilities.

### *(iii) Current and Deferred Tax Expense*

Current and deferred tax are recognized in the statement of profit and loss, except when they relate to items that are recognized in other comprehensive income or directly in equity, in which case, the current and deferred tax are also recognized in other comprehensive income or directly in equity respectively.

#### **k) Earnings Per share**

Basic earnings per share is being calculated by dividing net profit or loss for the year (including prior period items, if any) attributable to equity shareholders by the weighted average number of equity shares outstanding during the year.

For the purpose of calculating diluted earnings per share, the net profit or loss for the year attributable to equity shareholders and the weighted average number of shares outstanding during the year are adjusted for the effects of all dilutive potential equity shares.

#### **l) Operating Cycle**

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realisation in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

#### **m) Financial Instrument**

Financial assets and financial liabilities are recognised when a Company becomes a party to the contractual provisions of the instruments.

Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss.

All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace.

All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets

##### **Classification of financial assets**

Financial Assets that meet the following conditions are subsequently measured at amortised cost (except for financial assets that are designated As at fair value through profit or loss on initial recognition):

- i) the assets is held within a business model whose objective is to hold assets in order to collect contractual cash flows ; and
- ii) the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Financial Assets that meet the following conditions are subsequently measured at fair value through other comprehensive income (except for financial assets that are designated As at fair value through profit or loss on initial recognition):

- i) the assets is held within a business model whose objective is achieved both by collecting contractual cash flows and selling financial assets; and
- ii) the contractual terms of the instrument give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

Interest income is recognised in profit or loss for FVTOCI financial assets. For the purposes of recognising foreign exchange gains and losses, FVTOCI financial assets are treated as financial assets measured at amortised cost. Thus, the exchange differences on the amortised cost are recognised in profit or loss and other changes in the fair value of FVTOCI financial assets are recognised in other comprehensive income and accumulated under the heading of 'Reserve for financial assets through other comprehensive income'. When the investment is disposed of, the cumulative gain or loss previously accumulated in this reserve is reclassified to profit or loss.

All other financial assets are subsequently measured at fair value.

##### **Effective interest method**

The effective interest method is a method of calculating the amortised cost of a debt instrument and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the debt instrument, or, where appropriate, a shorter period, to the net carrying amount on initial recognition.

Income is recognised on an effective interest basis for debt instruments other than those financial assets classified As at FVTPL. Interest income is recognised in profit or loss and is included in the "Other income" line item.

##### **Financial assets at fair value through profit or loss (FVTPL)**

A financial asset that meets the amortised cost criteria or debt instruments that meet the FVTOCI criteria may be designated As at FVTPL upon initial recognition if such designation eliminates or significantly reduces a measurement or recognition inconsistency that would arise from measuring assets or liabilities or recognising the gains and losses on them on different bases. The Company has not designated any debt instrument As at FVTPL.

Financial assets at FVTPL are measured at fair value at the end of each reporting period, with any gains or losses arising on remeasurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any dividend or interest earned on the financial asset and is included in the 'Other income' line item. Dividend on financial assets at FVTPL is recognised when the Company's right to receive the dividends is established, it is probable that the economic benefits associated with the dividend will flow to the entity, the dividend does not represent a recovery of part of cost of the investment and the amount of dividend can be measured reliably.

#### **Impairment of financial assets**

The Company applies the expected credit loss model for recognising impairment loss on financial assets measured at amortised cost, debt instruments at FVTOCI, lease receivables, trade receivables, and other contractual rights to receive cash or other financial asset, and financial guarantees not designated As at FVTPL.

Expected credit losses are the weighted average of credit losses with the respective risks of default occurring as the weights. Credit loss is the difference between all contractual cash flows that are due to the Company in accordance with the contract and all the cash flows that the Company expects to receive (i.e. all cash shortfalls), discounted at the original effective interest rate (or credit-adjusted effective interest rate for purchased or originated credit impaired financial assets). The Company estimates cash flows by considering all contractual terms of the financial instrument (for example, prepayment, extension, call and similar options) through the expected life of that financial instrument.

The Company measures the loss allowance for a financial instrument at an amount equal to the lifetime expected credit losses if the credit risk on that financial instrument has increased significantly since initial recognition. If the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month expected credit losses. 12-month expected credit losses are portion of the life-time expected credit losses and represent the lifetime cash shortfalls that will result if default occurs within the 12 months after the reporting date and thus, are not cash shortfalls that are predicted over the next 12 months.

If the Company measured loss allowance for a financial instrument at lifetime expected credit loss model in the previous period, but determines at the end of a reporting period that the credit risk has not increased significantly since initial recognition due to improvement in credit quality as compared to the previous period, the Company again measures the loss allowance based on 12-month expected credit losses.

When making the assessment of whether there has been a significant increase in credit risk since initial recognition, the Company uses the change in the risk of a default occurring over the expected life of the financial instrument instead of the change in the amount of expected credit losses. To make that assessment, the Company compares the risk of a default occurring on the financial instrument As at the reporting date with the risk of a default occurring on the financial instrument As at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition.

For trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 115, the Company always measures the loss allowance at an amount equal to lifetime expected credit losses.

Further, for the purpose of measuring lifetime expected credit loss allowance for trade receivables, the Company has used a practical expedient as permitted under Ind AS 109. This expected credit loss allowance is computed based on a provision matrix which takes into account historical credit loss experience and adjusted for forward looking information.

The impairment requirements for the recognition and measurement of a loss allowance are equally applied to debt instruments at FVTOCI except that the loss allowance is recognised in other comprehensive income and is not reduced from the carrying amount in the balance sheet.

#### **Derecognition of financial assets**

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the asset and an associated liability for amounts it may have to pay. If the Company retains substantially all the risks and rewards of ownership of a transferred financial asset, the Company continues to recognise the financial asset and also recognises a collateralised borrowing for the proceeds received.

On derecognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in profit or loss if such gain or loss would have otherwise been recognised in profit or loss on disposal of that financial asset.

On derecognition of a financial asset other than in its entirety (e.g. when the Company retains an option to repurchase part of a transferred asset), the Company allocates the previous carrying amount of the financial asset between the part it continues to recognise under continuing involvement, and the part it no longer recognises on the basis of the relative fair values of those parts on the date of the transfer. The difference between the carrying amount allocated to the part that is no longer recognised and the sum of the consideration received for the part no longer recognised and any cumulative gain or loss allocated to it that had been recognised in other comprehensive income is recognised in profit or loss if such gain or loss would have otherwise been recognised in profit or loss on disposal of that financial asset. A cumulative gain or loss that had been recognised in other comprehensive income is allocated between the part that continues to be recognised and the part that is no longer recognised on the basis of the relative fair values of those parts.

**Foreign exchange gains and losses**

The fair value of financial assets denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of each reporting period. For foreign currency denominated financial assets measured at amortised cost and FVTPL, the exchange differences are recognised in statement of profit and loss since there are no designated hedging instruments in a hedging relationship.

**Financial liabilities**

All financial liabilities are subsequently measured at amortised cost using the effective interest method or at FVTPL.

However, financial liabilities that arise when a transfer of a financial asset does not qualify for derecognition or then the continuing involvement approach applies, financial guarantee contracts issued by the Company, and commitments issued by the Company to provide a loan at below-market interest rate are measured in accordance with the specific accounting policies set out below.

Financial liabilities are classified As at FVTPL when the financial liability is either contingent consideration recognised by the Company as an acquirer in a business combination to which Ind AS 103 applies or is held for trading or it is designated As at FVTPL.

A financial liability is classified as held for trading if:

- i) it has been incurred principally for the purpose of repurchasing it in the near term; or
- ii) on initial recognition it is part of a portfolio of identified financial instruments that the company manages together and has a recent actual pattern of short-term profit-taking; or
- iii) it is a derivative that is not designated and effective as a hedging instrument.

Financial liabilities at FVTPL are stated at fair value, with any gains or losses arising on remeasurement recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any interest paid on the financial liability and is included in the 'Other income' line item.

However, for non-held-for-trading financial liabilities that are designated As at FVTPL, the amount of change in the fair value of the financial liability that is attributable to changes in the credit risk of that liability is recognised in other comprehensive income, unless the recognition of the effects of changes in the liability's credit risk in other comprehensive income would create or enlarge an accounting mismatch in profit or loss, in which case these effects of changes in credit risk are recognised in profit or loss. The remaining amount of change in the fair value of liability is always recognised in profit or loss. Changes in fair value attributable to a financial liability's credit risk that are recognised in other comprehensive income are reflected immediately in retained earnings and are not subsequently reclassified to profit or loss.

Gains or losses on financial guarantee contracts and loan commitments issued by the Company that are designated by the Company As at fair value through profit or loss are recognised in profit or loss.

Financial liabilities subsequently measured at amortised cost

Financial liabilities that are not held-for-trading and are not designated As at FVTPL are measured at amortised cost at the end of subsequent accounting periods. The carrying amounts of financial liabilities that are subsequently measured at amortised cost are determined based on the effective interest method. Interest expense that is not capitalised as part of costs of an asset is included in the 'Finance costs' line item.

The effective interest method is a method of calculating the amortised cost of a financial liability and of allocating interest expense over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash payments (including all fees and points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial liability, or (where appropriate) a shorter period, to the net carrying amount on initial recognition.

**Financial guarantee contracts**

A financial guarantee contract is a contract that requires the issuer to make specified payments to reimburse the holder for a loss it incurs because a specified debtor fails to make payments when due in accordance with the terms of a debt instrument.

Financial guarantee contracts issued by a group entity are initially measured at their fair values and, if not designated As at FVTPL, are subsequently measured at the higher of:

- i) the amount of loss allowance determined in accordance with impairment requirements of Ind AS 109; and
- ii) the amount initially recognised less, when appropriate, the cumulative amount of income recognised in accordance with the principles of Ind AS115.

**Foreign exchange gains and losses**

For financial liabilities that are denominated in a foreign currency and are measured at amortised cost at the end of each reporting period, the foreign exchange gains and losses are determined based on the amortised cost of the instruments and are recognised in 'Other income'.

The fair value of financial liabilities denominated in a foreign currency is determined in that foreign currency and translated at the spot rate at the end of the reporting period. For financial liabilities that are measured As at FVTPL, the foreign exchange component forms part of the fair value gains or losses and is recognised in profit or loss.

**Derecognition of financial liabilities**

The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or have expired. An exchange between with a lender of debt instruments with substantially different terms is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. Similarly, a substantial modification of the terms of an existing financial liability (whether or not attributable to the financial difficulty of the debtor) is accounted for as an extinguishment of the original financial liability and the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in statement of profit and loss.

**n) Provisions & Contingencies**

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material). When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

**o) Contingent Liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by occurrence or non-occurrence of one or more of uncertain future events beyond the control of company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the an obligation. A contingent liability also arises in the extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably its existence in the financial statements. Company does not recognize the contingent liability but disclosed its existence in financial statements.

**p) Cash and Cash Equivalents**

Cash and cash equivalents for the purposes of cash flow statement are comprise of cash at bank and cash in hand and short-term investments with an original maturity of three months or less.

**26 Segmental Reporting****Operating segments**

Ind AS 108 "Operating Segment" ("Ind AS 108") establishes standards for the way that public business enterprises report information about operating segments and related disclosures about products and services, geographic areas, and major customers. Based on the "management approach" as defined in Ind AS 108, Operating segments are to be reported in a manner consistent with the internal reporting provided to the Chief Operating Decision Maker (CODM). The CODM evaluates the Company's performance and allocates resources on overall basis. The Company's sole operating segment is therefore 'Healthcare services'. Accordingly, there are no additional disclosure to be provided under Ind AS 108, other than those already provided in the financial statements.



27 Earning Per Share (EPS)

Particulars	Year ended 31st March, 2021	Period ended 31st March, 2020
<b>Net profit after Tax</b>	(93.09)	(124.77)
Profit / (Loss) attributable to the Equity Shareholders	(93.09)	(124.77)
Basic / Weighted Average Number of Equity Shares		
Outstanding during the period	34,93,151	18,19,413
Earning Per Share (in Rupees)		
- Basic	(2.66)	(6.86)
- Diluted	(2.66)	(6.86)
Nominal value of Equity Shares	10.00	10.00

28 The Micro, Small and Medium Enterprises have been identified by the Company from the available information, which has been relied upon by the auditors. According to such identification, the disclosures as per Section 22 of "The Micro, Small and Medium Enterprise Development (MSMED) Act, 2006" are as follows:

	Rs. In Lacs	Rs. In Lacs
	31st March, 2021	31st March, 2020
Details of dues to Micro and Small Enterprises as per MSMED Act, 2006		
The principal amount and the interest due thereon remaining unpaid to any supplier at the end of each accounting year	-	-
- Principal Amount	-	-
- Interest thereon	-	-
The amount of interest paid by the buyer in terms of section 16 of the Micro Small and Medium Enterprise Development Act, 2006 along with the amounts of the payment made to the supplier beyond the appointed day during each accounting year	-	-
The amount of interest due and payable for the period of delay in making payment (which have been paid but beyond the appointed day during the year) but without adding the interest specified under Micro Small and Medium Enterprise Development Act, 2006.	-	-
The amount of interest accrued and remaining unpaid at the end of the accounting year; and the amount of further interest remaining due and payable even in the succeeding years, until such date when the interest dues above are actually paid to the small enterprise for the purpose of disallowance as a deductible expenditure under section 23 of the Micro Small and Medium Enterprise Development Act, 2006.	-	-

29 Employee Benefits

**Defined contribution plan**

i) The company has recognized, in statement of Profit and Loss for year ended 31st March, 2021 an amount of Rs. 8.14 Lacs (Previous period Rs. 3.88 Lacs) under defined contribution plans.

	Year ended 31st March, 2021	Period ended 31st March, 2020
Expense under defined contribution plans include:		
a) Employer's contribution to provident fund	7.55	3.70
b) Employer's contribution to Employee State Insurance Corporation	0.50	0.14
c) Employer's contribution to Labour Welfare Fund	0.09	0.04
	<u>8.14</u>	<u>3.88</u>

The expense is disclosed in the line item - contribution to provident fund and other funds in Note 21

**Defined benefit plan**

i) The Company has a defined benefit gratuity plan. Every employee who has completed five years or more of the service gets a gratuity on retirement / termination at 15 days salary (last drawn salary) for each completed year of service. The Company has also provided for long-term compensated absences.

	Gratuity (unfunded)		Leaves (unfunded)	
	31st March, 2021	31st March, 2020	31st March, 2021	31st March, 2020
(i) Reconciliation of opening and closing balances of obligations:				
a) Obligation at the beginning	1.25	-	3.59	-
b) Current Service Cost	0.65	1.11	5.15	3.24
c) Interest Cost	0.08	-	0.24	-
d) Past Service Cost	-	0.14	-	0.44
e) Actuarial (Gain) / Loss	(0.92)	-	(0.56)	-
f) Benefits paid	-	-	(1.19)	(0.09)
g) Obligation at the period end	1.06	1.25	7.22	3.59
(ii) Change in Plan Assets (Reconciliation of opening and closing balances):				
a) Fair Value of Plan Assets at beginning	-	-	-	-
b) Prior Period Adjustment	-	-	-	-
c) Expected return on Plan Asset	-	-	-	-
d) Contributions	-	-	-	-
e) Benefits paid	-	-	-	-
f) Actuarial Gain / (Loss) on Plan Assets	-	-	-	-
g) Fair Value of Plan Assets at period end	-	-	-	-
(iii) Reconciliation of fair value of assets and obligations:				
a) Present value of obligation at period end	1.06	1.25	7.22	3.59
b) Fair Value of Plan Assets at period end	-	-	-	-
c) Asset / Liability recognized in the Balance Sheet	1.06	1.25	7.22	3.59
(iv) Amount recognized in the income statement				
a) Current Service Cost	0.65	1.11	5.15	3.24
b) Past Service Cost	-	0.14	-	0.44
c) Interest Cost	0.08	-	0.24	-
d) Curtailment Cost (Credit)	-	-	-	-
e) Expected return on Plan Assets	-	-	-	-
f) Actuarial (Gain) / Loss	(0.92)	-	(0.56)	-
g) Expenses recognized during the period	(0.19)	1.25	4.83	3.68
(v) Other Comprehensive Income (OCI)				
a) Unrealised actuarial Gain / (Loss)	0.92	-	0.56	-
(v) Assumptions:	As at 31st March, 2021		As at 31st March, 2020	
a) Discounting Rate (per annum)	6.76%		6.75%	
b) Future Salary Increase	5.50%		8.00%	
Withdrawal / Employee Turnover Rate				
c) Age upto 30 years	36.00%		20.00%	
d) Age from 31 to 44 years	32.00%		10.00%	
e) Age above 44 years	15.00%		10.00%	
Mortality table used	Indian Assured Lives Mortality (2012-14)		Indian Assured Lives Mortality (2012-14)	

The estimates of future salary increases, considered in actuarial valuation, take into account inflation, seniority, promotion and other relevant factors including supply and demand in the employment market.

Significant actuarial assumption for the determination of the defined obligation are discounted rate, expected salary escalation rate and withdrawal rate. The sensitivity analyses below have been determined based on reasonably possible changes of the respective assumption occurring at the end of the reporting period, while holding all other assumptions constant.

The above information is certified by the actuarial valuer.

Enterprise best estimate of contribution during next year is Rs. 1.22 Lacs for Gratuity & Rs. 4.78 Lacs for Leave Encashment.

The discount rate is based on prevailing market yield of Govt. Bonds as at the date of valuation.

Particulars	Year ended 31st March, 2021		Period ended 31st March, 2020	
	Increase	Decrease	Increase	Decrease
Change in discount rate by 0.50%	(0.16)	0.14	(0.22)	0.24
Change in Salary escalation rate by 0.50%	0.14	(0.16)	0.24	(0.22)

Sensitivity due to mortality and withdrawals are not material & hence impact of change not calculated.

Sensitivity as to rate of inflation, rate of increase of pensions in payment, rate of increase of pensions before retirement and life expectancy are not applicable being a lump sum benefit on retirement.

**Financial Instruments****i) Capital Management**

The Company manages its capital to ensure that the Company will be able to continue as going concern while maximising the return to stakeholders through the optimisation of the debt and equity balance.

The capital structure of the Company consists of net debt (borrowings as Detailed in Notes 13 & 15 offset by cash and bank balances) and total equity of the company.

The Company is not subject to any externally imposed capital requirements other than for covenants under various loan arrangements of the Company.

The Company's Board reviews the capital structure of the Company on need basis. As part of this review, the Board considers the cost of capital and the risks associated with each class of capital. The gearing ratio as 31st March 2021 169%( 343%, 31st March 2020)

**Gearing Ratio :**

The gearing ratio at end of the reporting period was as follows :

Particulars	(Rs. In Lacs)	
	As at March 31,2021	As at March 31,2020
Debt *	973.67	504.67
Less : Cash and Bank Balances (Refer Note 8 )	227.36	41.32
Net Debt	746.31	463.35
Total Equity	442.80	135.23
Net Debt to Equity Ratio	169%	343%

\* Debt is defined as long-term and short-term borrowings.

**ii) Categories of Financial Instruments**

Financial Assets	(Rs. In Lacs)	
	As at 31st March 2021	As at 31st March 2020
<b>Measured at amortised cost</b>		
Trade receivables - Current	174.35	9.04
Cash and cash equivalents - Current	227.36	41.32
Loans	0.74	0.77
Other Financial Assets	0.80	1.08
<b>Total</b>	<b>403.25</b>	<b>52.21</b>

At the end of the reporting period, there are no significant concentrations of financial assets designated at FVTPL. The carrying amount reflected above represents the Company's maximum exposure to credit risk for such financial assets.

Financial Liabilities	(Rs. In Lacs)	
	As at 31st March 2021	As at 31st March 2020
<b>Measured at amortised cost</b>		
Borrowings - Non Current	896.30	500.66
Borrowings - Current	-	-
Trade payables - Current	141.12	58.06
Other financial liabilities - Current	192.46	29.05
<b>Total</b>	<b>1,229.88</b>	<b>587.77</b>

**ii) Financial Risk Management Objectives**

The Company's Corporate Treasury function provides services to the business, co-ordinates access to domestic and international financial markets, monitors and manages the financial risks including market risk (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk.

The Board of Directors manages the financial risk of the Company through internal risk reports which analyse exposure by magnitude of risk. The Company has no exposure from the international market as the Company's operations are in India. The Company has no exposure towards foreign currency risk as it earns no revenue in foreign currency.

**Market Risk**

The Company's activities expose it primarily to the financial risks of changes in interest rates.

**a) Interest Rate risk management**

The Company is exposed to interest rate risk because Company borrow funds at both fixed and floating interest rates. The risk is managed by the Company by maintaining an appropriate mix between fixed and floating rate borrowings.

The Company's exposures to interest rates on financial assets and financial liabilities are detailed in the liquidity risk management section of this note.

### Interest Rate sensitivity analysis

The sensitivity analyses below have been determined based on the exposure to interest rates at the end of the reporting period. For floating rate liabilities, the analysis is prepared assuming the amount of the liability outstanding at the end of the reporting period was outstanding for the whole year. A 100 basis point increase or decrease is used when reporting interest rate risk internally to key management personnel and represents management's assessment of the reasonably possible change in interest rates.

Particulars	(Rs. In Lacs)	(Rs. In Lacs)
	Interest Impact As at 31st March 2021	Interest Impact As at 31st March 2020
<b>If increase by 1% in interest rates</b>		
Increase / (decrease) in profit or loss for the year/period	(9.67)	(5.01)
Increase / (decrease) in total equity as at the end of the reporting period	(9.67)	(5.01)
<b>If decrease by 1% in interest rates</b>		
Increase / (decrease) in profit or loss for the year/period	9.67	5.01
Increase / (decrease) in total equity as at the end of the reporting period	9.67	5.01

#### b) Credit Risk Management

Credit risk refers to the risk that a counter party will default on its contractual obligations resulting in financial loss to the Company. The Company takes due care while extending any credit as per the approval matrix approved by Board of Directors.

#### c) Liquidity risk management

Ultimate responsibility for liquidity risk management rests with the board of directors, which has established an appropriate liquidity risk management framework for the management of the company's short-term, medium-term and long-term funding and liquidity management requirements. The Company manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities, by continuously monitoring forecast and actual cash flows, and by matching the maturity profiles of financial assets and liabilities. Note given below sets out details of additional undrawn facilities that the Company has at its disposal to further reduce liquidity risk.

#### Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it will have sufficient liquidity to meet its liabilities when they are due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The table below provides details regarding the undiscounted contractual maturities of significant financial liabilities

Particulars	Rs. In Lacs				
	Within 1 year	1 - 2 years	More than 2 years	Total	Carrying Amount (net of transaction cost)
<b>As at 31st March 2021</b>					
Borrowings	70.57	173.04	723.26	966.87	966.87
Trade Payables	141.12	-	-	141.12	141.12
Interest accrued but not due on borrowings	6.80			6.80	6.80
Other Financial Liabilities	115.09			115.09	115.09
<b>Total</b>	<b>333.58</b>	<b>173.04</b>	<b>723.26</b>	<b>1,229.88</b>	<b>1,229.88</b>
<b>As at 31st March 2020</b>					
Borrowings	-	34.22	466.44	500.66	500.66
Trade Payables	58.06	-	-	58.06	58.06
Interest accrued but not due on borrowings	4.01			4.01	4.01
Other Financial Liabilities	25.04			25.04	25.04
<b>Total</b>	<b>87.11</b>	<b>34.22</b>	<b>466.44</b>	<b>587.77</b>	<b>587.77</b>

### 31 Related party disclosure

#### a) Name of related parties

##### Parties where control exists irrespective of whether transactions have occurred or not

Ultimate Parent Company Constructive Finance Private Limited

Holding Company Artemis Medicare Services Limited

##### Names of other related parties with whom transactions have taken place during the year

Key Management Personnel Mr. Arpit Jain (CEO)

Enterprises having significant influence Philips Medical Systems Nederland BV

b) Transactions during the year

(Rs. In Lacs)

Particulars	Holding Company		Key Management Personnel & their relatives		Enterprises having significant influence	
	For the year/Period ended		For the year/Period ended		For the year/Period ended	
	31st March, 2021	31st March, 2020	31st March, 2021	31st March, 2020	31st March, 2021	31st March, 2021
Purchase of Property, Plant & Equipment	316.79	6.74			-	
Expenses incurred on behalf of the Company	1.17	20.77			-	
Corporate Guarantee Fee	0.63	0.48				
Purchase of medical consumables	6.12	1.96				
Interest on Inter Corporate Loan	0.78	-				
Issue of Share Capital	260.00	169.00			140.00	91.00
<b>KMP-Compensation</b>						
Arpit Jain			33.72	50.51		
<b>Defined Benefit Obligation (DBO) (At year end)</b>						
Arpit Jain						
Post-Employment Benefits			0.59	0.57		
Short-term benefits			3.03	1.44		
<b>Total - DBO</b>			<b>3.63</b>	<b>2.01</b>		

\* Transactions are reported including taxes.

(Rs. In Lacs)

Balance Payable	Name of Related Party	31st March, 2021	31st March, 2021
Key Management Personnel & their relatives	Mr. Arpit Jain	3.57	4.05
Holding Company	Artemis Medicare Services Limited	66.68	-

32 Disclosure under Ind AS - 115 (Revenue from contracts with customers)

	31st March 2021	31st March 2020
	(Rs. In Lacs)	(Rs. In Lacs)
<b>a. Disaggregated revenue information</b>		
<b>Type of Services or goods</b>		
Revenue from Healthcare Services	510.07	152.93
Revenue from Sales of Drugs and Consumables	129.40	39.97
<b>Total</b>	<b>639.47</b>	<b>192.90</b>
<b>Revenue from Contracts with Customers</b>		
Revenue from Customers based in India	639.47	192.90
<b>Total</b>	<b>639.47</b>	<b>192.90</b>
<b>Timing of Revenue Recognition</b>		
Services transferred over time ( Healthcare Services)	510.07	152.93
Goods (Pharmacy and consumable) transferred at a point of time	129.40	39.97
<b>Total</b>	<b>639.47</b>	<b>192.90</b>
<b>b. Trade receivables and Contract Customers</b>		
Trade Receivables (includes GST)	174.35	9.04
Unbilled revenue	0.80	1.08
<b>Total</b>	<b>175.15</b>	<b>10.12</b>

Trade receivables are non-interest bearing and are generally on terms of 0- 90 days. Rs. Nil was recognised as provision for expected credit losses on trade receivables.

Trade receivables are presented net of impairment in the Balance sheet.

c. Performance obligation and remaining performance obligation

The remaining performance obligation disclosure provides the aggregate amount of the transaction price yet to be recognized as at the end of the reporting period and an explanation as to when the Company expects to recognize these amounts in revenue. There were no remaining performance obligation as the same is satisfied upon delivery of goods/services."

33 Lease

The company incurred Rs.1.28 lacs for the year ended March 31,2021 (Previous period Rs 1.42 Lacs) towards expenses relating to short term leases and leases of low value assets.

34

The Parliament of India has approved the Code on Social Security, 2020(the Code) which may impact the contribution by the Company towards provident fund, gratuity and ESI. The Code have been published in Gazette of India however, the effective date has not yet been notified. The Company will assess the impact of the code when it comes into effect and will record any related impact in the period the Code becomes effective,if any.

- 35 The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. The Company has considered the possible effects of Covid-19 on the carrying amounts of Property, Plant and Equipment, Trade Receivable and Other Current Assets. In developing the assumptions relating to the possible future uncertainties in the economic conditions because of this pandemic, the company, as at the date of approval of the financial statements, has used external and internal sources of information/indicators to estimate the future performance of the Company. Based on current estimates the Company expects the carrying amount of these assets to be recovered. However, the impact assessment of COVID-19 is a continuing process given the uncertainties associated with its nature and duration and accordingly the impact may be different from that estimated as at the date of approval of these financial statements. The Company will continue to monitor any material changes to future economic conditions.
- 36 The Company was incorporated on 14th January, 2019 so the comparative figures are for the period 14th January 2019 to 31st March 2020 thereby not comparable with current year figures.

As per our report of even date attached  
For SCV & Co. LLP  
Chartered Accountants  
Firm Registration Number 000235N / N500089

SD/-  
(Rajiv Puri)  
Partner  
Membership No. 084318

Place : New Delhi  
Dated: 7th May 2021

For and on behalf of the Board of Directors  
of Artemis Cardiac Care Private Limited

SD/-  
Dr. Devlina Chakravarty  
[Director]  
[DIN : 07107875]

SD/-  
Dr. MS Sandhu  
[Director]  
[DIN : 08409644]

Place : Gurugram  
Dated: 7th May 2021

SD/-  
Arpit Jain  
[CEO]

SD/-  
Shilpa Budhia  
[Company Secretary]